Mirtazapina Flas Kern Pharma (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Kern Pharma, is a tetracyclic antidepressant presented as an oral tablet for oral use. It treats major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapina Flas Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and is used to alleviate symptoms of major depression.

Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. Depressive episodes associated with major depression: helps restore sleep patterns and appetite. Treatment‑resistant depression: may be added when first‑line antidepressants are insufficient.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction or jaundice

When prescribing mirtazapine, clinicians should consider several safety aspects.

Assess hepatic function: evaluate liver enzymes before initiation and during therapy. Monitor weight and metabolic parameters: watch for significant weight gain and lipid changes. Caution in cardiovascular disease: be aware of orthostatic hypotension and possible arrhythmias. Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. Use cautiously in the elderly: increased risk of sedation and falls. Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensives: potential additive hypotensive effect. - Carbamazepine: may reduce mirtazapine concentrations, lowering efficacy.